Authors
Keywords
Abstract
Gubenyiliu II, GY II for short is a representative type of Traditional Chinese Medicine (TCM) widely used for breast cancer treatment with good outcomes in China for several decades. However, the biological basis of GY II remains to be holistically elucidated. In this study, an experimental method of network pharmacology and experiments in vitro were proposed to explore more exact efficacy and potential mechanisms of GYII. First, corresponding potential target genes both for GII components and breast cancer were extracted from established databases. 205 compounds in13 herbs of GY II and 265 antitumor or immune-related genes were investigated based on network-based, large-scale target prediction. Furthermore, with intersection genes of GYII and breast cancer were mapped, the Protein-Protein Internetwork (PPI) network of shared genes was constructed. Then Kyoto Encyclopaedia of Genes and Genomes (KEGG) functional annotation clusters were acquired and presented as top 25 pathways. Meanwhile 3 typical ingredients, such as kaempferol, luteolin and quercetin of all the components, were verified by high performance liquid chromatography (HPLC). At last, the cell viability, proliferation, migration, cycles, apoptosis, the changes of cell morphology, molecular mechanism of TCM inhibiting tumor cell in vitro experiments were carried out for efficiency verification. In conclusion, this study suggested great potentials in tumor immune microenvironment regulation and tumor prevention of GY II herbs generally, and provided a systematic strategy for unveiling the commonness in the biological basis of GY II in breast cancer treatment.
